TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) will post its quarterly earnings results before the market opens on Wednesday, May 15th. Persons interested in listening to the company’s earnings conference call can do so using this link.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last announced its earnings results on Monday, April 1st. The company reported ($1.56) earnings per share for the quarter. The firm had revenue of $5.72 million during the quarter.
TriSalus Life Sciences Trading Up 0.9 %
Shares of NASDAQ TLSI opened at $9.71 on Wednesday. TriSalus Life Sciences has a 12-month low of $3.32 and a 12-month high of $16.24. The firm’s 50-day simple moving average is $9.64 and its 200 day simple moving average is $7.91.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Garmin Navigates to New Highs Driven By Wearables Trend
- Insider Buying Explained: What Investors Need to Know
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What is an Earnings Surprise?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
